A Phase IIIA Study of Immunogenicity and Safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
GlaxoSmithKline
Description
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline (GSK) Biologicals' investigational quadrivalent split virion influenza vaccine FLU-Q-QIV in adults 18 years of age and older.
Citations (0)
No citations found
It looks like this dataset has no citations.
Mentions (0)
No mentions found
It looks like this dataset has not been mentioned in any sources.
Metrics Over Time
Publication Details
DOI
Publisher
Vivli
License
Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/
Subfield
Epidemiology
Field
Medicine
Domain
Health Sciences
Confidence Score
60%
Source
Scholar Data Model
Keywords
Conditions: InfluenzaInterventions: FLULAVAL® QUADRIVALENT